Skip NavigationSkip to Content
Return Return to Search Results

Therapeutic responses to Roseomonas mucosa in atopic dermatitis may involve lipid-mediated TNF-related epithelial repair

  1. Author:
    Myles, Ian A [ORCID]
    Castillo, Carlo R [ORCID]
    Barbian, Kent D [ORCID]
    Kanakabandi, Kishore [ORCID]
    Virtaneva, Kimmo [ORCID]
    Fitzmeyer, Emily [ORCID]
    Paneru, Monica
    Otaizo-Carrasquero, Francisco [ORCID]
    Myers, Timothy G [ORCID]
    Markowitz,Tovah
    Moore, Ian N [ORCID]
    Liu, Xue [ORCID]
    Ferrer, Marc
    Sakamachi, Yosuke
    Garantziotis, Stavros [ORCID]
    Swamydas, Muthulekha [ORCID]
    Lionakis, Michail S
    Anderson, Erik D [ORCID]
    Earland, Noah J [ORCID]
    Ganesan, Sundar
    Sun, Ashleigh A [ORCID]
    Bergerson, Jenna R E
    Silverman, Robert A [ORCID]
    Petersen, Maureen [ORCID]
    Martens, Craig A
    Datta, Sandip K [ORCID]

  2. Author Address

    Epithelial Therapeutics Unit, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, MD, USA. mylesi@niaid.nih.gov., Laboratory of Clinical Immunology and Microbiology, NIAID, NIH, Bethesda, MD, USA., RTS Genomics Unit, Rocky Mountain Laboratories, NIAID, NIH, Hamilton, MT, USA., Genomic Technologies Section, NIAID, NIH, Bethesda, MD, USA., NIAID Collaborative Bioinformatics Resource (NCBR), NIAID, NIH, Bethesda, MD, USA., Advanced Biomedical Computational Science, Frederick National Laboratory for Cancer Research, Frederick, MD, USA., Infectious Disease Pathogenesis Section, Comparative Medicine Branch, NIAID, NIH, Rockville, MD, USA., Department of Pre-clinical Innovation, National Center for Advancing Translational Sciences, NIH, Rockville, MD, USA., National Institute of Environmental Health Sciences, Research Triangle, NC, USA., Fungal Pathogenesis Section, LCIM, NIAID, NIH, Bethesda, MD, USA., Biological Imaging Section, Research Technology Branch, NIAID, NIH, Bethesda, MD, USA., Department of Pediatrics, Georgetown University Hospital, Washington, DC, USA., Walter Reed National Military Medical Center, Bethesda, MD, USA.,
    1. Year: 2020
    2. Date: Sep 09
  2. Journal: Science translational medicine
    1. 12
    2. 560
    3. Pages: pii: eaaz8631
  4. Type of Article: Article
  5. Article Number: eaaz8631
  6. ISSN: 1946-6234
  1. Abstract:

    Dysbiosis of the skin microbiota is increasingly implicated as a contributor to the pathogenesis of atopic dermatitis (AD). We previously reported first-in-human safety and clinical activity results from topical application of the commensal skin bacterium Roseomonas mucosa for the treatment of AD in 10 adults and 5 children older than 9 years of age. Here, we examined the potential mechanism of action of R. mucosa treatment and its impact on children with AD less than 7 years of age, the most common age group for children with AD. In 15 children with AD, R. mucosa treatment was associated with amelioration of disease severity, improvement in epithelial barrier function, reduced Staphylococcus aureus burden on the skin, and a reduction in topical steroid requirements without severe adverse events. Our observed response rates to R. mucosa treatment were greater than those seen in historical placebo control groups in prior AD studies. Skin improvements and colonization by R. mucosa persisted for up to 8 months after cessation of treatment. Analyses of cellular scratch assays and the MC903 mouse model of AD suggested that production of sphingolipids by R. mucosa, cholinergic signaling, and flagellin expression may have contributed to therapeutic impact through induction of a TNFR2-mediated epithelial-to-mesenchymal transition. These results suggest that a randomized, placebo-controlled trial of R. mucosa treatment in individuals with AD is warranted and implicate commensals in the maintenance of the skin epithelial barrier. Copyright © 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.

    See More

  1. Keywords:

External Sources

  1. View Full Text
  2. DOI: 10.1126/scitranslmed.aaz8631
  3. PMID: 32908007
  4. View record in Web of Science®
  5. WOS: 000567648900005
  6. PII : 12/560/eaaz8631

Library Notes

  1. Fiscal Year: FY2020-2021
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel